ARC-II in locally advanced pancreatic carcinoma
Research type
Research Study
Full title
A Phase II study in patients with locally advanced pancreatic carcinoma: ARC-II – Akt-inhibition by Nelfinavir plus chemoradiation with gemcitabine and cisplatin
IRAS ID
4736
Sponsor organisation
The University of Oxford
Eudract number
2008-006302-42
ISRCTN Number
N/A
Research summary
The 5-year survival rate of patients with pancreatic carcinoma is only 1-4%. One of the factors in this is the current lack of effective therapy. Unusual expression of genes that share a common signalling pathway are known. One such pathway is the phosphatidylinositol 3-kinase (PI3K)-Akt pathway. It has been shown that blockage of Akt (a protein within the cell) can assist the response to radiation in vitro and in vivo. Since this signalling pathway is often activated in tumour cells but not host cells it is a good target candidate to block to increase the sensitivity to radiotherapy. A set of drugs in common practice for HIV therapy (HIV protease inhibitors) block this pathway, one such drug is Nelfinavir. We propose to use Nelfinavir in combination with the current standard care of chemoradiation (radiotherapy, gemcitabine and cisplatin) to investigate its effect in the treatment of pancreatic carcinoma. A successful phase 1 study (12 patients) of this regime carried out by Dr Brunner has initiated the request for this UK phase II study funded by the NIHR Oxford Biomedical Research Centre.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
09/H0604/36
Date of REC Opinion
13 May 2009
REC opinion
Further Information Favourable Opinion